CommercialPrior AuthHigh impact
Diabetic GLP-1 and GIP/GLP-1 drug coverage reminder
Harvard Pilgrim Health Care·Endocrinology, Family Medicine, Internal Medicine +1 more·Pharmacy
Effective date
May 1, 2026
We identified it
Jun 20, 2026
Summary
Starting May 1, 2026, Harvard Pilgrim Health Care Commercial and Tufts Health Direct will require prior authorization for ALL diabetic GLP-1 and GIP/GLP-1 medications (Mounjaro, Ozempic, Trulicity, etc.), removing the current automated step therapy program. Previously, these medications were automatically covered if patients had prior oral diabetes medication claims within 365 days.
Action Required
Before May 1, 2026: Billing team must update prior authorization workflows for all Harvard Pilgrim Commercial and Tufts Health Direct members requesting diabetic GLP-1 and GIP/GLP-1 medications (Bydureon BCise, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity). Providers must submit requests through medical review process with documentation of type 2 diabetes diagnosis and trial/failure of oral hypoglycemic agent. Update encounter forms and EMR templates to prompt for required documentation. Claims will be denied without proper prior authorization.